样式: 排序: IF: - GO 导出 标记为已读
-
-
Predictors of the efficacy of His bundle pacing in patients with a prolonged PR interval: A stratified analysis of the HOPE‐HF randomized controlled trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-18 Daniel Keene, Nandita Kaza, Divya Srinivasan, Nadine Ali, Mark Tanner, Paul Foley, Badri Chandrasekaran, Philip Moore, Shaumik Adhya, Norman Qureshi, Amal Muthumala, Rebecca Lane, Aldo Rinaldi, Sharad Agarwal, Francisco Leyva, Jonathan Behar, Sukh Bassi, Andre Ng, Paul Scott, Rachana Prasad, Jon Swinburn, Joseph Tomson, Amarjit Sethi, Jaymin Shah, Phang Boon Lim, Andreas Kyriacou, Dewi Thomas, Jenny
AimsThe randomized, double‐blind, placebo‐controlled HOPE‐HF trial assessed the benefit of atrio‐ventricular (AV) delay optimization delivered using His bundle pacing. It recruited patients with left ventricular ejection fraction ≤40%, PR interval ≥200 ms, and baseline QRS ≤140 ms or right bundle branch block. Overall, there was no significant increase in peak oxygen uptake (VO2max) but there was significant
-
Catheter‐based ablation to improve outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction: Rationale and design of the CABA‐HFPEF‐DZHK27 trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-18 Abdul S. Parwani, Stefan Kääb, Tim Friede, Roland Richard Tilz, Johann Bauersachs, Norbert Frey, Gerhard Hindricks, Thorsten Lewalter, Michiel Rienstra, Andreas Rillig, Daniel Scherr, Daniel Steven, Paulus Kirchhof, Burkert Pieske
AimsAtrial fibrillation (AF) is common in heart failure (HF) and negatively impacts outcomes. The role of ablation‐based rhythm control in patients with AF and HF with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) is not known. The CABA‐HFPEF‐DZHK27 (CAtheter‐Based Ablation of atrial fibrillation compared to conventional treatment in patients with Heart Failure with Preserved Ejection
-
Reply to ‘Sex hormones and heart failure’ Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-18 Jungeun Lim, Jason Y.Y. Wong
-
Dilemmas in recommending exercise for prevention of heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Edimar Alcides Bocchi, Bruno Biselli, Guilherme Veiga Guimarães
-
Clinical features, haemodynamics, and outcomes of heart failure with preserved ejection fraction in coarctation of aorta Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Alexander C. Egbe, Yogesh N.V. Reddy, Ahmed E. Ali, Ahmed Younis, Barry A. Borlaug
AimsThere are similarities in the pathogenesis of cardiac remodelling and dysfunction in heart failure with preserved ejection fraction (HFpEF) and coarctation of aorta (COA). We hypothesized that clinical HFpEF would be highly prevalent in adults with COA, and that the presence of HFpEF would increase the risk of mortality in this population. The aim of this study was to define the clinical features
-
Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics? Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Pierpaolo Pellicori, Joe J. Cuthbert, Andrew L. Clark, John G.F. Cleland
-
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Yogesh N.V. Reddy, Varun Sundaram
-
Diabetic myocardial disorder – a complex interaction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Katharina Marx‐Schütt, Jan Biegus
-
Association of baseline and longitudinal changes in insulin‐like growth factor‐binding protein‐7 with the risk of incident heart failure: Data from the PREVEND study Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Sabrina Abou Kamar, Valentina Bracun, Maissa El‐Qendouci, Nils Bomer, Stephan J.L. Bakker, Ron T. Gansevoort, Eric Boersma, Isabella Kardys, Rudolf A. de Boer, Navin Suthahar
-
Pulmonary congestion assessed by lung ultrasound in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: Prevalence and prognostic implications Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-17 Rosa Lillo, Stefano Cangemi, Francesca Graziani, Gabriella Locorotondo, Daniela Pedicino, Cristina Aurigemma, Enrico Romagnoli, Silvia Malara, Maria Chiara Meucci, Giulia Iannaccone, Francesco Bianchini, Marialisa Nesta, Piergiorgio Bruno, Antonella Lombardo, Carlo Trani, Francesco Burzotta
-
High variability in assays of blood markers of collagen turnover in cardiovascular disease: Implications for research and clinical practice Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-09 Pawel Piotr Rubiś, Ewa Dziewięcka, Arantxa González, John G.F. Cleland
Fibrosis is a common feature of many chronic diseases, including heart failure, which can have deleterious effects on cardiac structure and function that are associated with adverse outcomes. By-products of collagen synthesis and degradation, such as carboxy- and amino-terminal pro- or telo-peptides of collagen type I and III (PICP, PINP, PIIINP, and CITP) have been extensively investigated as markers
-
European Society of Cardiology quality indicators update for the care and outcomes of adults with heart failure. The Heart Failure Association of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-12 Amr Abdin, Chris Wilkinson, Suleman Aktaa, Michael Böhm, Marija Polovina, Giuseppe Rosano, Mitja Lainscak, Lars H. Lund, Theresa McDonagh, Marco Metra, Marianna Adamo, Richard Mindham, Massimo Piepoli, Magdy Abdelhamid, Stefan Störk, Maria P. Tokmakova, Petar Seferović, Andrew J.S. Coats, Chris P. Gale
AimsTo update the European Society of Cardiology (ESC) quality indicators (QIs) for the evaluation of the care and outcomes of adults with heart failure.Methods and resultsThe Working Group comprised experts in heart failure including members of the ESC Clinical Practice Guidelines Task Force for heart failure, members of the Heart Failure Association, and a patient representative. We followed the
-
How, when, and who: Composing the puzzle of family screening in hereditary cardiac amyloidosis Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-10 Giuseppe Limongelli, Giuseppe Palmiero
-
Plasma soluble fms‐like tyrosine kinase‐1, placental growth factor, and vascular endothelial growth factor system gene variants as predictors of survival in heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-09 Melinda A. Paterson, Anna P. Pilbrow, Chris M. Frampton, Vicky A. Cameron, Richard W. Troughton, Chris J. Pemberton, Mayanna Lund, Gerard P. Devlin, A. Mark Richards, Robert N. Doughty, Barry R. Palmer
-
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from EMPULSE Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-09 João Pedro Ferreira, Jonathan P. Blatchford, John R. Teerlink, Mikhail N. Kosiborod, Christiane E. Angermann, Jan Biegus, Sean P. Collins, Jasper Tromp, Michael E. Nassif, Mitchell A. Psotka, Josep Comin‐Colet, Robert J. Mentz, Martina Brueckmann, Matias Nordaby, Piotr Ponikowski, Adriaan A. Voors
AimsPatients hospitalized for acute heart failure (HF) could be enrolled in EMPULSE (NCT04157751) upon haemodynamic stabilization and between 24 h and 5 days after hospital admission. The timing of treatment initiation may influence the efficacy and safety of drugs such as empagliflozin. The aim of this study was to evaluate patient characteristics, clinical events, and treatment effects according
-
Initial combination therapy with macitentan and tadalafil in patients with pulmonary arterial hypertension, with and without cardiac comorbidities Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-05 Vallerie V. McLaughlin, Olivier Sitbon, Kelly M. Chin, Nazzareno Galiè, Marius M. Hoeper, David G. Kiely, Gwen MacDonald, Nicolas Martin, Stephen C. Mathai, Andrew Peacock, Ahmed Tawakol, Adam Torbicki, Anton Vonk Noordegraaf, Stephan Rosenkranz
-
Iron deficiency and supplementation in patients with heart failure: Results from the IRON‐HF international survey Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-04 Massimiliano Camilli, Federico Ballacci, Valentina Alice Rossi, Antonio Cannatà, Luca Monzo, Nathan Mewton, Nicolas Girerd, Piero Gentile, Marco Marini, Massimo Mapelli, Andreas J. Flammer, Nadia Aspromonte, Rocco Antonio Montone, Antonella Lombardo, Gaetano Antonio Lanza, Gianluigi Savarese, Frank Ruschitzka, Filippo Crea
AimsIron deficiency (ID) is common in patients with heart failure (HF) and is associated with poor outcomes, regardless of anaemia status. Iron supplementation has been demonstrated to improve exercise capacity and quality of life in patients with HF with an ejection fraction <50% and ID. This survey aimed to provide data on real‐world practices related to ID screening and management.Methods and resultsWe
-
Aortic valve disease and heart failure with mildly reduced ejection fraction: New insights and pending questions Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-04 Gaspard Suc, Bernard Iung
-
Hypoalbuminaemia and heart failure: A practical review of current evidence Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-04 Marta Biancucci, Riccardo Barbiero, Benedetta Pennella, Antonio Cannatà, Walter Ageno, Flavio Tangianu, Andrea Maria Maresca, Francesco Dentali, Aldo Bonaventura
Hypoalbuminaemia (serum albumin levels ≤3.5 g/dl) is associated with poor outcomes among patients with heart failure (HF). This narrative review includes original articles and reviews published over the past 20 years and retrieved from PubMed using the following search terms (or their combination): ‘heart failure’, ‘hypoalbuminaemia’, ‘heart failure with reduced ejection fraction’, ‘heart failure with
-
Combined tricuspid and left‐sided valvular heart disease: A frequent and treatable scenario Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-03 Giovanni Benfari, Paolo Springhetti, Maurice Enriquez‐Sarano
-
Why left atrial venting fails to influence extracorporeal life support survival in cardiogenic shock: Unravelling the intricate reality of unloading Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-03 Aurore Ughetto, Christophe Vandenbriele, Clément Delmas
Over the past decade, extracorporeal life support (ECLS) has gained increasing utilization in the management of refractory cardiogenic shock (CS) with a class IIaC recommendation according to the latest European and US guidelines.1 However, recent randomized controlled trials (RCTs) and meta-analyses can be considered inconclusive in demonstrating the benefit of ECLS compared with optimal medical treatment
-
Haemodynamic contributors to pulmonary hypertension across the spectrum of adult congenital heart disease Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-07-03 Yogesh N.V. Reddy, William R. Miranda, Christopher C. Jain, Barry A. Borlaug, Alexander C. Egbe
AimsAdult congenital heart disease (ACHD) includes multiple disease states that predispose to pulmonary hypertension (PH). Haemodynamically, PH depends on abnormalities in three components: pulmonary blood flow (Qp), pulmonary vascular resistance (PVR) and pulmonary venous pressure (PVP). We sought to evaluate the prevalence and prognostic impact of individual haemodynamic abnormalities in ACHD.Methods
-
What's new in heart failure? June–July 2024 Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-28 Alberto Aimo, Pau Codina, Matthew M.Y. Lee, Daniela Tomasoni
-
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-28 Giorgia Panichella, Daniela Tomasoni, Alberto Aimo
-
-
When the heart and lung play in concert and pulmonary hypertension is the common ‘musical leitmotif’ of cardiopulmonary diseases Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-27 Marco Guazzi
-
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant‐level pooled analysis from the CANVAS Program and CREDENCE trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-27 Muthiah Vaduganathan, Christopher P. Cannon, Meg J. Jardine, Hiddo J.L. Heerspink, Clare Arnott, Brendon L. Neuen, Ashish Sarraju, Jagadish Gogate, Jochen Seufert, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Mikhail N. Kosiborod
-
Towards more practical phenotyping in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-27 Yogesh N.V. Reddy, Varun Sundaram
-
Left atrial enlargement and biomarker profiles: Time for integration of biomarkers and echocardiography in heart failure prevention Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-27 Jasper Tromp, Wouter Ouwerkerk
-
Long‐term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-27 Brian Drachman, Thibaud Damy, Mazen Hanna, Ronnie Wang, Franca S. Angeli, Pablo Garcia‐Pavia
-
Cardiovascular‐kidney‐metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON‐HF Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-27 Mats C.H. Lassen, John W. Ostrominski, Brian L. Claggett, Milton Packer, Michael Zile, Akshay S. Desai, Amil M. Shah, Maja Cikes, Bela Merkely, Mauro Gori, Xiaowen Wang, Sheila M. Hegde, Marc A. Pfeffer, Martin Lefkowitz, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
-
A novel controlled metabolic accelerator for the treatment of obesity‐related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-26 Dalane W. Kitzman, Gregory D. Lewis, Ambarish Pandey, Barry A. Borlaug, Andrew J. Sauer, Sheldon E. Litwin, Kavita Sharma, Diane K. Jorkasky, Shaharyar Khan, Sanjiv J. Shah
AimsCompared with those without obesity, patients with obesity‐related heart failure with preserved ejection fraction (HFpEF) have worse symptoms, haemodynamics, and outcomes. Current weight loss strategies (diet, drug, and surgical) work through decreased energy intake rather than increased expenditure and cause significant loss of skeletal muscle mass in addition to adipose tissue. This may have
-
-
OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-23 Riccardo M. Inciardi, Muthiah Vaduganathan, Carlo M. Lombardi, Cristina Gussago, Piergiuseppe Agostoni, Pietro Ameri, Nadia Aspromonte, Leonardo Calò, Matteo Cameli, Erberto Carluccio, Stefano Carugo, Manlio Cipriani, Raffaele De Caterina, Gaetano M. De Ferrari, Michele Emdin, Alessandra Fornaro, Marco Guazzi, Massimo Iacoviello, Massimo Imazio, Maria Teresa La Rovere, Sergio Leonardi, Marta Maccallini
Patients with heart failure (HF) remain often undertreated for multiple reasons, including treatment inertia, contraindications, and intolerance. The OPTIimal PHARMacological therapy for patients with Heart Failure (OPTIPHARM-HF) registry is designed to evaluate the prevalence of evidence-based medical treatment prescription and titration, as well as the causes of its underuse, in a broad real-world
-
C‐reactive protein, inflammation and short‐term mortality in acute heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-24 Gad Cotter, Matteo Pagnesi, Beth Davison
-
What's new in heart failure? May–June 2024 Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-24 Alberto Aimo, Pau Codina, Matthew M.Y. Lee, Daniela Tomasoni
-
Incremental value of C‐reactive protein to the MEESSI acute heart failure risk score Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-24 Desiree Wussler, Maria Belkin, Samyut Shrestha, Hannah Wernicke, Androniki Papachristou, Albina Nowak, Fatima Aliyeva, Constantin Mork, Ivo Strebel, Gabrielle Valerie Francoi Huré, Dominic Weil, Eleni Michou, Nikola Kozhuharov, Danielle M. Gualandro, Christian Puelacher, Oscar Miró, Xavier Rossello, Francisco Javier Martín‐Sánchez, Stuart J. Pocock, Assen Goudev, Tobias Breidthardt, Christian Mueller
-
Correction to “Iron deficiency in heart failure: Screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine measurements collaborative project” Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-24
Lindberg F, Lund LH, Benson L, Linde C, Orsini N, Carrero JJ, et al. Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project. Eur J Heart Fail 2023;25:1270–1280. https://doi.org/10.1002/ejhf.2879 In the Graphical Abstract of the original published version, the labels for
-
Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-24 Christian Nitsche, Adam Ioannou, Rishi K. Patel, Yousuf Razvi, Aldostefano Porcari, Muhammad U. Rauf, Francesco Bandera, Alberto Aimo, Michele Emdin, Ana Martinez‐Naharro, Lucia Venneri, Aviva Petrie, Ashutosh Wechalekar, Helen Lachmann, Philip N. Hawkins, Julian D. Gillmore, Marianna Fontana
AimsTransthyretin cardiac amyloidosis (ATTR‐CA) is stratified into prognostic categories using the National Amyloidosis Centre (NAC) staging system. The aims of this study were to further expand the existing NAC staging system to incorporate an additional disease stage that would identify patients at high risk of early mortality.Methods and resultsThe traditional NAC staging system (stage 1: N‐terminal
-
Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-24 Mingming Yang, Toru Kondo, Pardeep S. Jhund, Marco Antonio Alcocer‐Gamba, C. Jan Willem Borleffs, Chern‐En Chiang, Josep Comin‐Colet, Akshay S. Desai, Dan Dobreanu, Jarosław Drożdż, Yaling Han, Stefan P. Janssens, Tzvetana Katova, Mikhail N. Kosiborod, Carolyn S.P. Lam, Béla Merkely, Vinh Nguyen Pham, Jorge Thierer, Muthiah Vaduganathan, Subodh Verma, Scott D. Solomon, John J.V. McMurray
-
Prevention and rehabilitation after heart transplantation: A clinical consensus statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a section of ESOT Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-19 Maria Simonenko, Dominique Hansen, Josef Niebauer, Maurizio Volterrani, Stamatis Adamopoulos, Cristiano Amarelli, Marco Ambrosetti, Stefan D. Anker, Antonio Bayes-Genis, Tuvia Ben Gal, T. Scott Bowen, Francesco Cacciatore, Giuseppe Caminiti, Elena Cavaretta, Ovidiu Chioncel, Andrew J.S. Coats, Alain Cohen-Solal, Flavio D'Ascenzi, Carmen de Pablo Zarzosa, Andreas B. Gevaert, Finn Gustafsson, Hareld
Little is known either about either physical activity patterns, or other lifestyle-related prevention measures in heart transplantation (HTx) recipients. The history of HTx started more than 50 years ago but there are still no guidelines or position papers highlighting the features of prevention and rehabilitation after HTx. The aims of this scientific statement are (i) to explain the importance of
-
Physician-directed patient self-management in heart failure using left atrial pressure: Interim insights from the VECTOR-HF I and IIa studies Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-20 David Meerkin, Leor Perl, Tal Hasin, Shalva Petriashvili, Levan Kurashvili, Mikheil Metreveli, Hüseyin Ince, Sebastian Feickert, Manhal Habib, Oren Caspi, Michael Jonas, Ignacio J. Amat-Santos, Antoni Bayes-Genis, Pau Codina, Oran Koren, Shir Frydman, Rachel M. Pachino, Stefan D. Anker, William T. Abraham
-
Characterization of serum phosphate levels over time with intravenous ferric carboxymaltose versus placebo as treatment for heart failure with reduced ejection fraction and iron deficiency: An exploratory prospective substudy from HEART-FID Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-19 Nina Nouhravesh, Jyotsna Garg, Frank W. Rockhold, Carmine G. De Pasquale, Eileen O'Meara, Gregory D. Lewis, Javed Butler, Josephine Harrington, Justin A. Ezekowitz, Piotr Ponikowski, Richard W. Troughton, Yee Weng Wong, Nicole Blackman, Syed Numan, Robert Adamczyk, Adrian F. Hernandez, Robert J. Mentz
-
Remote haemodynamic monitoring and the next step: Involving the patient in the self‐management of heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-20 Jasper J. Brugts
-
Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-19 Petar M. Seferović, Walter J. Paulus, Giuseppe Rosano, Marija Polovina, Mark C. Petrie, Pardeep S. Jhund, Carsten Tschöpe, Naveed Sattar, Massimo Piepoli, Zoltán Papp, Eberhard Standl, Mamas A. Mamas, Paul Valensi, Ales Linhart, Nebojša Lalić, Antonio Ceriello, Wolfram Döhner, Arsen Ristić, Ivan Milinković, Jelena Seferović, Francesco Cosentino, Marco Metra, Andrew J.S. Coats
-
Prevalence and prognosis of aortic valve diseases in patients hospitalized with heart failure with mildly reduced ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-19 Tobias Schupp, Noah Abel, Moritz Schmidberger, Mila Kathrin Höpfner, Alexander Schmitt, Marielen Reinhardt, Jan Forner, Felix Lau, Muharrem Akin, Jonas Rusnak, Ibrahim Akin, Michael Behnes
Data regarding the characterization and outcomes of patients with heart failure (HF) with mildly reduced ejection fraction (HFmrEF) is scarce. This study investigates the characteristics and prognostic impact of native aortic valve diseases (AVD) in patients with HFmrEF.
-
Right ventricular dysfunction and impaired right ventricular–pulmonary arterial coupling in paradoxical low-flow, low-gradient aortic stenosis Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-17 Richard J. Nies, Felix S. Nettersheim, Simon Braumann, Svenja Ney, Laurin Ochs, Johannes Dohr, Jasper F. Nies, Hendrik Wienemann, Matti Adam, Victor Mauri, Stephan Baldus, Stephan Rosenkranz
-
Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-17 Steven A. Muller, Belén Peiró-Aventin, Giulia Biagioni, Giacomo Tini, Giulia Saturi, Christina Kronberger, Anouk Achten, Stephan Dobner, Wouter P. te Rijdt, Alessio Gasperetti, Anneline S.J.M. te Riele, Guerino G. Varrà, Alberto Ponziani, Alexander Hirsch, Aldostefano Porcari, Manon G. van der Meer, Mattia Zampieri, Pim van der Harst, Andreas Kammerlander, Elena Biagini, J. Peter van Tintelen, Emanuele
-
Survival and ability to return to work 1 year after extracorporeal membrane oxygenation for acute heart or lung failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-14 Lea Haebel, Jan Fuge, Christian Kuehn, Marius M Hoeper, Johann Bauersachs
Patients experiencing acute or end-stage heart or lung failure continue to display a high mortality rate, which ranges between 40–55% across various disease aetiologies, countries and studies.1 One invasive procedure for providing short-term support in critically ill patients involves extracorporeal membrane oxygenation (ECMO).2, 3 Especially in cardiogenic shock associated with acute myocardial infarction
-
Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG-HF Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-14 Geert Voordes, Beth Davison, Jan Biegus, Christopher Edwards, Kevin Damman, Jozine ter Maaten, Alexandre Mebazaa, Koji Takagi, Marianna Adamo, Andrew P. Ambrosy, Mattia Arrigo, Marianela Barros, Jelena Celutkiene, Kamilė Čerlinskaitė-Bajorė, Ovidiu Chioncel, Alain Cohen-Solal, Albertino Damasceno, Benjamin Deniau, Rafael Diaz, Gerasimos Filippatos, Etienne Gayat, Antoine Kimmoun, Carolyn S.P. Lam,
Biologically active adrenomedullin (bio-ADM) is a promising marker of residual congestion. The STRONG-HF trial showed that high-intensity care (HIC) of guideline-directed medical therapy (GDMT) improved congestion and clinical outcomes in heart failure (HF) patients. The association between bio-ADM, decongestion, outcomes and the effect size of HIC of GDMT remains to be elucidated.
-
Right heart failure with left ventricular assist devices: Preoperative, perioperative and postoperative management strategies. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-10 Stamatis Adamopoulos, Michael Bonios, Tuvia Ben Gal, Finn Gustafsson, Magdy Abdelhamid, Marianna Adamo, Antonio Bayes-Genis, Michael Böhm, Ovidiu Chioncel, Alain Cohen-Solal, Kevin Damman, Concetta Di Nora, Shahrukh Hashmani, Loreena Hill, Tiny Jaarsma, Ewa Jankowska, Yury Lopatin, Marco Masetti, Mandeep R. Mehra, Davor Milicic, Brenda Moura, Wilfried Mullens, Sanem Nalbantgil, Chrysoula Panagiotou
Right heart failure (RHF) following implantation of a left ventricular assist device (LVAD) is a common and potentially serious condition with a wide spectrum of clinical presentations with an unfavourable effect on patient outcomes. Clinical scores that predict the occurrence of right ventricular (RV) failure have included multiple clinical, biochemical, imaging and haemodynamic parameters. However
-
Circulating beta-hydroxybutyrate levels in advanced heart failure with reduced ejection fraction: Determinants and prognostic impact Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-10 Luca Monzo, Jan Kovar, Barry A. Borlaug, Jan Benes, Martin Kotrc, Katerina Kroupova, Antonin Jabor, Janka Franekova, Vojtech Melenovsky
-
In-hospital and long-term outcomes of cardiogenic shock complicating myocardial infarction versus heart failure Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-10 Ki Hong Choi, Danbee Kang, Hyejeong Park, Taek Kyu Park, Joo Myung Lee, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Juhee Cho, Jeong Hoon Yang
-
Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-07 Stefan D. Anker, Tim Friede, Ralph Stephan von Bardeleben, Javed Butler, Muhammad Shahzeb Khan, Monika Diek, Jutta Heinrich, Martin Geyer, Marius Placzek, Roberto Ferrari, William T. Abraham, Ottavio Alfieri, Angelo Auricchio, Antoni Bayes-Genis, John G.F. Cleland, Gerasimos Filippatos, Finn Gustafsson, Wilhelm Haverkamp, Malte Kelm, Karl-Heinz Kuck, Ulf Landmesser, Aldo P. Maggioni, Marco Metra, Vlasis
-
Prognostic utility of cardiopulmonary exercise testing with simultaneous exercise echocardiography in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-06 Ayami Naito, Kazuki Kagami, Naoki Yuasa, Tomonari Harada, Hidemi Sorimachi, Fumitaka Murakami, Yuki Saito, Yuta Tani, Toshimitsu Kato, Naoki Wada, Takeshi Adachi, Hideki Ishii, Masaru Obokata
Cardiopulmonary exercise testing (CPET) combined with exercise echocardiography (CPETecho) allows simultaneous assessments of cardiac, pulmonary, and ventilation in heart failure (HF) with preserved ejection fraction (HFpEF). This study sought to determine whether simultaneous assessment of CPET variables could provide additive predictive value over exercise stress echocardiography in patients with
-
Mechanisms of myocardial reverse remodelling and its clinical significance: A scientific statement of the ESC Working Group on Myocardial Function Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-04 Inês Falcão-Pires, Ana Filipa Ferreira, Fábio Trindade, Luc Bertrand, Michele Ciccarelli, Valeria Visco, Dana Dawson, Nazha Hamdani, Linda W. Van Laake, Frank Lezoualc'h, Wolfgang A. Linke, Ida G Lunde, Peter P. Rainer, Mahmoud Abdellatif, Jolanda Van der Velden, Nicola Cosentino, Alessia Paldino, Giulio Pompilio, Serena Zacchigna, Stephane Heymans, Thomas Thum, Carlo Gabriele Tocchetti
-
Pulmonary hypertension across the spectrum of left heart and lung disease Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-04 Barry A. Borlaug, Brett Larive, Robert P. Frantz, Paul Hassoun, Anna Hemnes, Evelyn Horn, Jane Leopold, Franz Rischard, Erika Berman-Rosenzweig, Gerald Beck, Serpil Erzurum, Samar Farha, J. Emanuel Finet, Kristin B. Highland, Miriam Jacob, Christine Jellis, Reena Mehra, Rahul Renapurkar, Harsimran Singh, W.H. Wilson Tang, Rebecca Vanderpool, Jennifer Wilcox, Shilin Yu, Nicholas Hill
Patients with pulmonary hypertension (PH) are grouped based upon clinical and haemodynamic characteristics. Groups 2 (G2, left heart disease [LHD]) and 3 (G3, lung disease or hypoxaemia) are most common. Many patients display overlapping characteristics of heart and lung disease (G2–3), but this group is not well-characterized.
-
Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA) Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-04 Domingo Pascual-Figal, Julio Núñez Villota, Maria Teresa Pérez-Martínez, José Ramón González-Juanatey, Mikel Taibo-Urquía, Pau Llàcer Iborra, Javier González-Martín, Sandra Villar, Meritxel Soler, Sonia Mirabet, Alberto Aimo, Alejandro Riquelme-Pérez, Manuel Anguita Sánchez, Manuel Martínez-Sellés, Pedro L. Sánchez, Borja Ibáñez, Antoni Bayés-Genís
-
Diuretics in pregnancy: Data from the ESC Registry of Pregnancy and Cardiac disease (ROPAC) Eur. J. Heart Fail. (IF 16.9) Pub Date : 2024-06-04 Johanna A. van der Zande, Matthias Greutmann, Daniel Tobler, Karishma P. Ramlakhan, Jerome M. J. Cornette, Magalie Ladouceur, Nicholas Collins, Dawn Adamson, Vijaya P. Paruchuri, Roger Hall, Mark R. Johnson, Jolien W. Roos-Hesselink